August 7, 2014 Below is a pdf for MTSL Issue #784 of the Medical Technology Stock Letter.
To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.
Tag: ISIS
MTSL Issue #782 – Deals, Data & IPOs Lead Solid End Of Q2
July 3, 2014 Below is a pdf for MTSL Issue #782 of the Medical Technology Stock Letter.
To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.
MTSL Issue #780 – The FDA Clinical Trials Process – A Primer
May 29, 2014 Below is a pdf for Issue 780 of the Medical Technology Stock Letter.
To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.
Isis Update (4-30-14)
ISIS Delivers Mixed SMN Data and Phase III Program Details at AAN: ISISâ stock has sold off due to mixed data for SMN-Rx in infants and children. There is not a lot of new data and most of it shows a benefit. However, the negative focus has been on patient deaths that were not drug[…]
To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.
Biotech Fund Managers – What The Pros Do Every Year
August 21, 2014 The Medical Technology Stock Letter (“MTSLâ€) prides itself on identifying exciting small companies that will become leaders in their respective fields over time. We emphasize “over time†because that is the nature of drug development and compounded returns of successful biotech stocks over the years vastly exceed that of the overall market. […]
To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.
A BRIEF IMMUNE-ONCOLOGY UPDATE
June 12, 2014 ASCO 2014 – Immune Oncology Rises to the Top – As many expected, immune oncology (I-O) was all the rage at the recently concluded American Society of Clinical Oncology (ASCO) meeting. While it is widely acknowledged that before ASCO, Bristol was the leader in the space followed by Merck, and Roche. At[…]
NOT YOUR FATHER’S PLATFORMS
MTSL published Issue #753 “Plentiful Platforms†on April 25, 2012. Most of our platform recommendations have made significant progress since then, and our subscriber base has grown substantially as well.
To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.
MTSL Issue #776 – Bios Go From First To Worst – Have We Reached Bottom?
April 3, 2014 Below is a pdf for MTSL Issue #776 of the Medical Technology Stock Letter.
To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.
MTSL Issue #783 – MTSL Portfolio H2:14 Event Calendar
July 17, 2014 Below is a pdf for MTSL Issue #783 of the Medical Technology Stock Letter.
To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.
MTSL Issue #781 – A BRIEF IMMUNE-ONCOLOGY UPDATE
June 12, 2014 Below is a pdf for MTSL Issue #781 of the Medical Technology Stock Letter.
To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.
MTSL Issue #779 – Not Your Father’s Platforms
May 15, 2014 Below is a pdf for Issue 779 of the Medical Technology Stock Letter.
To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.
MTSL Issue #774 – The Beat Goes On, But Not Without Skipping A Beat Or Two
March 6, 2014 Below is a pdf for MTSL Issue #774 of the Medical Technology Stock Letter.
To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.